Cited by 1,490Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Open access

Herbst, Roy S., Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E., Sandler, Alan, Kris, Mark G., Tran, Hai T., Klein, Pam, Li, Xin, Ramies, David, Johnson, David H., Miller, Vincent A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.02.840

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non-small-cell lung cancer (NSCLC). Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC. PATIENTS AND METHODS: TRIBUTE randomly assigned patients with good performance status and previously untreated advanced (stage IIIB/IV) NSCLC to erlotinib 150 mg/d or placebo combined with up to six cycles of carboplatin and paclitaxel, followed by maintenance monotherapy with erlotinib. Random assignment was stratified by stage, weight loss in the previous 6 months, measurable disease, and treatment center. The primary end point was overall survival (OS). Secondary end points included time to progression (TTP), objective response (OR), and duration of response. RESULTS: There were 1,059 assessable patients (526 erlotinib; 533 placebo). Median survival for patients treated with erlotinib was 10.6 v 10.5 months for placebo (hazard ratio, 0.99; 95% CI, 0.86 to 1.16; P = .95). There was no difference in OR or median TTP. Patients who reported never smoking (72 erlotinib; 44 placebo) experienced improved OS in the erlotinib arm (22.5 v 10.1 months for placebo), though no other prespecified factors showed an advantage in OS with erlotinib. Erlotinib and placebo arms were equivalent in adverse events (except rash and diarrhea). CONCLUSION: Erlotinib with concurrent carboplatin and paclitaxel did not confer a survival advantage over carboplatin and paclitaxel alone in patients with previously untreated advanced NSCLC. Never smokers treated with erlotinib and chemotherapy seemed to experience an improvement in survival and will undergo further investigation in future randomized trials.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.02.840

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
DECLARATION OF HELSINKI.
Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,069

Show all 25 references

Sorted by citations

Items 301–400 of 1,000

Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 69
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Senderowicz, A. M., Johnson, J. R., Sridhara, R., Zimmerman, P., Justice, R. L., & Pazdur, R. (2007) · PubMed · Cited by 65
A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer
Lynch, T. J., Fenton, D. W., Hirsh, V., Bodkin, D., Middleman, E. L., Chiappori, A., Halmos, B., Favis, R., Liu, H., Trepicchio, W. L., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181aba89f · Cited by 65
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines
Cheng, H., An, S., Zhang, X., Dong, S., Yi-fang, Z., Chen, Z., Chen, H., Guo, A., Lin, Q., & Wu, Y.-L. L. C. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1347-4 · Cited by 64
Tailoring Ras-pathway—Inhibitor combinations for cancer therapy
Blum, R., & Kloog, Y. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.11.002 · Cited by 66
New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer
Provencio, M., Sánchez, A., Garrido, P., & Valcárcel, F. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.012 · Cited by 64
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Grossi, F., Aita, M., Defferrari, C., Rosetti, F., Brianti, A., Fasola, G., Vinante, O., Pronzato, P., & Pappagallo, G. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0260 · Cited by 64
Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
Thomas, A., Rajan, A., López-Chávez, A., Wang, Y., & Giaccone, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds478 · Cited by 63
State of the Art in Therapy for Non-Small Cell Lung Cancer
Laskin, J. J., & Sandler, A. B. (2005) · Cancer Investigation · doi:10.1081/cnv-200067172 · Cited by 63
Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Bonomi, P., Buckingham, L. E., & Coon, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0332 · Cited by 62
ZD6474 – clinical experience to date
Heymach, J. V. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602604 · Cited by 63
Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer
Lopes, G. L., Vattimo, E. F. D. Q., & de Castro, G. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000004531 · Cited by 69
Epidermal Growth Factor Receptor as a Therapeutic Target in Human Thyroid Carcinoma: Mutational and Functional Analysis
Mitsiades, C. S., Kotoula, V., Poulaki, V., Sozopoulos, E., Negri, J. M., Charalambous, E., Fanourakis, G., Voutsinas, G. E., Tseleni‐Balafouta, S., & Mitsiades, N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0055 · Cited by 62
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib
Ling, Y., Li, T., Perez-Soler, R., & Haigentz, M. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0902-8 · Cited by 62
Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma
Sakurada, A., Lara-Guerra, H., Liu, G., Shepherd, F. A., & Tsao, M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168be93 · Cited by 63
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib
Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63
Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site
Hainsworth, J. D., Spigel, D. R., Thompson, D. S., Murphy, P. B., Lane, C. M., Waterhouse, D. M., Naot, Y., & Greco, F. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0112 · Cited by 62
Interstitial Lung Disease in Lung Cancer
Danson, S. J., Blackhall, F. H., Hulse, P. A., & Ranson, M. (2005) · Drug Safety · doi:10.2165/00002018-200528020-00002 · Cited by 62
Treatment of Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., de Marinis, F., Cappuzzo, F., Maïo, M. D., Hirsch, F. R., Mok, T. S. K., Morgillo, F., Rosell, R., Spigel, D. R., Yang, J. C., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.002 · Cited by 60
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation
Chung, C., & Christianson, M. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212474047 · Cited by 62
Loss of the endothelial glycocalyx is associated with increased E-selectin mediated adhesion of lung tumour cells to the brain microvascular endothelium
Rai, S., Nejadhamzeeigilani, Z., Gutowski, N. J., & Whatmore, J. L. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0223-9 · Cited by 61
Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Mumenthaler, S. M., Foo, J., Leder, K., Choi, N. C., Agus, D. B., Pao, W. J., Mallick, P., & Michor, F. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200270v · Cited by 61
Esophagogastric cancer: Targeted agents
Ku, G. Y., & Ilson, D. H. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.009 · Cited by 59
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Lee, C., Shiao, H., Wang, W.-C., & Hsieh, H. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.928283 · Cited by 60
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells
Ko, J., Ciou, S., Cheng, C., Wang, L., Hong, J.-H., Jheng, M.-Y., Ling, S.-T., & Lin, Y. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn130 · Cited by 60
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Rukazenkov, Y., Speake, G., Marshall, G. B., Anderton, J., Davies, B. R., Wilkinson, R. W., Hickinson, D. M., & Swaisland, A. J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833034e1 · Cited by 59
Fluorescence In situ Hybridization Subgroup Analysis of TRIBUTE, a Phase III Trial of Erlotinib Plus Carboplatin and Paclitaxel in Non–Small Cell Lung Cancer
Hirsch, F. R., Varella‐Garcia, M., Dziadziuszko, R., Xiao, Y., Gajapathy, S., Skokan, M. C., Lin, M., O’Neill, V., & Bunn, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0539 · Cited by 59
Integrating molecular diagnostics into anticancer drug discovery
Peták, I., Schwab, R. E., Őrfi, L., Kopper, L., & Kéri, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3135 · Cited by 58
The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib
Fidler, M. J., Argiris, A. E., Patel, J. D., Johnson, D. H., Sandler, A. B., Villaflor, V. M., Coon, J. S., Buckingham, L. E., Kaiser, K. A., Basu, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4013 · Cited by 58
Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making
Scott, A., & Salgia, R. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.577 · Cited by 59
Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Riely, G. J., & Miller, V. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0544 · Cited by 58
Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring
Joerger, M., Kraff, S., Huitema, A. D. R., Feiss, G. L., Moritz, B., Schellens, J. H. M., Beijnen, J. H., & Jaehde, U. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261934 · Cited by 56
Lung Cancer in Never Smokers
Török, S., Hegedűs, B., László, V., Hoda, M. A., Ghanim, B., Berger, W., Klepetko, W., Döme, B., & Ostoros, G. (2011) · Future Oncology · doi:10.2217/fon.11.100 · Cited by 56
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment
Blank, S. V., Christos, P. J., Curtin, J. P., Goldman, N. A., Runowicz, C. D., Sparano, J. A., Liebes, L., Chen, H. X., & Muggia, F. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.008 · Cited by 56
Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and FluorescenceIn situHybridization—Why, When, and How?
Dziadziuszko, R., Hirsch, F. R., Varella‐Garcia, M., & Bunn, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0087 · Cited by 56
A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer
Rodriguez, C. P., Adelstein, D. J., Rice, T. W., Rybicki, L. A., Videtic, G. M. M., Saxton, J. P., Murthy, S. C., Mason, D. P., & Ives, D. I. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c5e334 · Cited by 56
Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer
Riely, G. J., Rizvi, N. A., Kris, M. G., Milton, D. T., Solit, D. B., Rosen, N. X., Senturk, E., Azzoli, C. G., Brahmer, J. R., Sirotnak, F. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4656 · Cited by 56
Gefitinib for the treatment of non-small-cell lung cancer
Hida, T., Ogawa, S., Park, J. C., Park, J. Y., Shimizu, J., Horio, Y., & Yoshida, K. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.9.1.17 · Cited by 58
Gefitinib Plus Chemotherapy Versus Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer Patients with Brain Metastases (GAP BRAIN): An Open-Label, Randomized, Multicenter, Phase 3 Study
Hou, X., Li, M., Wu, G., Feng, W., Su, J., Jiang, H., Jiang, G., Chen, J., Zhang, B., You, Z., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.55050 · Cited by 56
Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update
Ayoola, A., Barochia, A., Belani, K., & Belani, C. P. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.666691 · Cited by 56
Clinical experience with gefitinib: An update
Cappuzzo, F., Finocchiaro, G., Metro, G., Bartolini, S., Magrini, E., Cancellieri, A., Trisolini, R., Castaldini, L., Tallini, G., & CRINO, L. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.008 · Cited by 54
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
Morgillo, F., Cascone, T., D’Aiuto, E., Martinelli, E., Troiani, T., Saintigny, P., Palma, R. D., Heymach, J. V., Berrino, L., Tuccillo, C., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.244 · Cited by 53
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Neal, J. W., & Nguyen, K.-S. H. (2012) · Biologics · doi:10.2147/btt.s26558 · Cited by 53
Strategies to Enhance Epidermal Growth Factor Inhibition: Targeting the Mevalonate Pathway
Dimitroulakos, J., Lorimer, I. A. J., & Goss, G. D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0089 · Cited by 53
Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review
Bachet, J., Peuvrel, L., Bachmeyer, C., Reguiaï, Z., Gourraud, P., Bouché, O., Ychou, M., Bensadoun, R., Dréno, B., & André, T. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0365 · Cited by 53
The Landscape of EGFR Pathways and Personalized Management of Non-Small-Cell Lung Cancer
Liang Cheng, C., Zhang, S., Alexander, R. E., Yao, Y., MacLennan, G. T., Pan, C.-X., Huang, J., Wang, M., Montironi, R., & Antonio Lopez-beltran, B. (2011) · Future Oncology · doi:10.2217/fon.11.25 · Cited by 53
Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non–Small Cell Lung Cancer: Independent Review of Four PROFILE Trials
Yoneda, K. Y., Scranton, J. R., Cadogan, M. A., Tassell, V. R., Nadanaciva, S., Wilner, K. D., & Stollenwerk, N. S. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.03.004 · Cited by 54
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
Fury, M. G., Solit, D. B., Su, Y. B., Rosen, N. X., Sirotnak, F. M., Smith, R. P., Azzoli, C. G., Gomez, J. E., Miller, V. A., Kris, M. G., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0286-6 · Cited by 53
Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study
Paccagnella, A., Oniga, F., Bearz, A., Favaretto, A. G., Clerici, M., Barbieri, F., Riccardi, A., Chella, A., Tirelli, U., Ceresoli, G. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2722 · Cited by 53
Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer
Douillard, J., Pirker, R., O'Byrne, K. J., Kerr, K. M., Störkel, S., von Heydebreck, A., Grote, H. J., Celik, I., & Shepherd, F. A. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000141 · Cited by 53
Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis
Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, A. G., Rouleau, T., Cooksley, C. D., Halm, J. K., Vithala, M. V., et al. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1821-8 · Cited by 55
Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
Abdullah, S. E., Haigentz, M., & Piperdi, B. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/351210 · Cited by 52
Rhabdomyolysis Resulting from Pharmacologic Interaction Between Erlotinib and Simvastatin
Veeraputhiran, M. K., & Sundermeyer, M. L. (2008) · Clinical Lung Cancer · doi:10.3816/clc.2008.n.036 · Cited by 52
Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
de Marinis, F., & Grossi, F. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-14 · Cited by 52
Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Wasil, T., & Lichtman, S. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-602 · Cited by 52
Targeted therapy in the treatment of solid tumors: Practice contradicts theory
Zhukov, N. V., & Tjulandin, S. A. (2008) · Biochemistry (Moscow) · doi:10.1134/s000629790805012x · Cited by 52
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
Jimeno, A., & Hidalgo, M. M. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.008 · Cited by 55
Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC): Results of OPN-017
Borghaei, H., Langer, C. J., Millenson, M. M., Ruth, K. J., Litwin, S., Tuttle, H., Seldomridge, J. S., Rovito, M. A., Mintzer, D. M., Cohen, R. B., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f50e · Cited by 52
Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer
Maalouf, G. E., Tourneau, C. L., Batty, G. N., Faivre, S. J., & Raymond, É. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.10.002 · Cited by 52
DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial
Payne, M., Ellis, P., Dunlop, D. J., Ranson, M., Danson, S. J., Schacter, L., & Talbot, D. C. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31631-2 · Cited by 52
Conclusion
Bunn, P. A., & Thatcher, N. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-37 · Cited by 52
The Risk for Anemia with Targeted Therapies for Solid Tumors
Barni, S., Cabiddu, M., Guarneri, P., Lonati, V., & Petrelli, F. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0024 · Cited by 51
Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis
Liu, Z.-L., Zhu, W., Zhou, W., Ying, H., Zheng, L., Guo, Y., Chen, J., & Shen, X. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60034-0 · Cited by 51
EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Wu, M., Zhao, J., Song, S. W., Zhuo, M., Wang, X., Bai, H., Wang, S., Yang, L., An, T., Zhang, Y., et al. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.011 · Cited by 51
EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality
Milano, G. A., Spano, J., & Leyland-Jones, B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604373 · Cited by 51
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
Tiseo, M. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s6594 · Cited by 51
Fool’s gold, lost treasures, and the randomized clinical trial
Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
Gridelli, C., Maione, P., Rossi, A., Ferrara, M. L., Bareschino, M. A., Schettino, C., Sacco, P. C., & Ciardiello, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0152 · Cited by 51
Chemotherapy dose–response relationships in non-small cell lung cancer and implied resistance mechanisms
Stewart, D. J., Chiritescu, G., Dahrouge, S., Banerjee, S., & Tomiak, E. M. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.12.002 · Cited by 51
A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
You, B., Tourneau, C. L., Chen, E. X., Wang, L. E., Jarvi, A., Bharadwaj, R. R., Kamel‐Reid, S., Perez‐Ordoñez, B., Mann, V., & Siu, L. L. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31820dbdcc · Cited by 51
Bioluminescent Orthotopic Mouse Models of Human Localized Non-Small Cell Lung Cancer: Feasibility and Identification of Circulating Tumour Cells
Mordant, P., Loriot, Y., Lahon, B., Castier, Y., Lesèche, G., Soria, J., Vozenin, M., Decraene, C., & Deutsch, É. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026073 · Cited by 51
A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer
Wang, S., Peng, L., Li, J., Zeng, X., Ouyang, L., Tan, C., & Lu, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055917 · Cited by 50
Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes
Wheatley‐Price, P., & Shepherd, F. A. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f335a3 · Cited by 49
Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells
Kuroda, H., Takeno, M., Murakami, S., Miyazawa, N., Kaneko, T., & Ishigatsubo, Y. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.03.015 · Cited by 50
Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation
Davies, A. M., Ho, C., Beckett, L. A., Lau, D. H., Scudder, S., Lara, P. N., Perkins, N., & Gandara, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a94b08 · Cited by 49
Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC)
Metro, G., Finocchiaro, G., Toschi, L., Bartolini, S., Magrini, E., Cancellieri, A., Trisolini, R., Castaldini, L., Tallini, G., Crinò, L., et al. (2006) · Reviews on Recent Clinical Trials · doi:10.2174/157488706775246157 · Cited by 50
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 52
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
Yoshimura, N., Kudoh, S., Mitsuoka, S., Yoshimoto, N., Oka, T., Nakai, T., Suzumura, T., Matusura, K., Tochino, Y., Asai, K., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.002 · Cited by 48
A phase II trial of cisplatin, fixed dose‐rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102
Philips, G. K., Halabi, S., Sanford, B. L., Bajorin, D. F., Small, E. J., & Cancer and Leukaemia Group B (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07226.x · Cited by 49
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Ganjoo, K. N., & Wakelee, H. A. (2007) · PubMed Central · Cited by 49
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
Mayer, E. L., Partridge, A. H., Harris, L. N., Gelman, R. S., Schumer, S., Burstein, H. J., & Winer, E. P. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0366-5 · Cited by 49
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Hanrahan, E. O., & Heymach, J. V. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0539 · Cited by 49
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Herbst, R. S., & Sandler, A. B. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0108 · Cited by 49
Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Toschi, L., & Cappuzzo, F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-2-211 · Cited by 48
Will targeted therapy hold its promise? An evidence-based review
Murdoch, D., & Sager, J. A. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f44b12 · Cited by 49
Salvage Therapy for Advanced Non-Small Cell Lung Cancer: Factors Influencing Treatment Selection
Ramalingam, S. S., & Sandler, A. B. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-655 · Cited by 50
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Layman, R. M., Ruppert, A. S., Lynn, M., Mrózek, E., Ramaswamy, B., Lustberg, M. B., Wesolowski, R., Ottman, S., Carothers, S., Bingman, A. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2112-2 · Cited by 48
Erlotinib-Induced Skin Rash in Patients with Non–Small-Cell Lung Cancer: Pathogenesis, Clinical Significance, and Management
Tsimboukis, S., Merikas, I., Karapanagiotou, E. M., Saif, M. W., & Syrigos, K. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.013 · Cited by 48
EGFR FISH versus mutation: Different tests, different end-points
Cappuzzo, F. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.02.008 · Cited by 49
Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment
Moran, C. A. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.057 · Cited by 46
Tissue Banking, Bioinformatics, and Electronic Medical Records: The Front-End Requirements for Personalized Medicine
Suh, K. S., Sarojini, S., Youssif, M., Nalley, K., Milinovikj, N., Elloumi, F., Russell, S., Pecora, A. L., Schecter, E., & Goy, A. H. (2013) · Journal of Oncology · doi:10.1155/2013/368751 · Cited by 48
Volumetric-modulated arc therapy (VMAT) for whole brain radiotherapy: not only for hippocampal sparing, but also for reduction of dose to organs at risk
Sood, S. S., Pokhrel, D., McClinton, C., Lominska, C. E., Badkul, R., Jiang, H., & Wang, F. (2017) · Medical dosimetry · doi:10.1016/j.meddos.2017.07.005 · Cited by 48
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
Pasini, L., & Ulivi, P. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070998 · Cited by 48
Dacomitinib, a new therapy for the treatment of non-small cell lung cancer
Brzezniak, C. E., Carter, C. A., & Giaccone, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758714 · Cited by 48
Targeting growth factors in lung cancer.
Hodkinson, P., Mackinnon, A., & Sethi, T. (2008) · Chest · doi:10.1378/chest.07-2680 · Cited by 51
Molecular-targeted therapies: Lessons from years of clinical development
Rosa, D. D., Ismael, G., Lago, L. D., & Awada, A. H. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.019 · Cited by 48
Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology
Maitland, M. L., Hudoba, C., Snider, K. L., & Ratain, M. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0669 · Cited by 48
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
Giaccone, G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi129 · Cited by 47

Authors: Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., Ramies, D., Johnson, D. H., & Miller, V. A.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Herbst, Roy S.
Johnson, Bruce E.
Sandler, Alan
Kris, Mark G.
Tran, Hai T.
Li, Xin
Ramies, David
Johnson, David H.
Miller, Vincent A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 5892-5899
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.02.840
OpenAlex: W2162724777
Cited by: 1,490
References: 25
Citations by year: 2026: 9 · 2025: 4 · 2024: 7 · 2023: 11 · 2022: 19 · 2021: 24 · 2020: 29 · 2019: 22 · 2018: 32 · 2017: 48 · 2016: 56 · 2015: 83 · 2014: 79 · 2013: 122 · 2012: 96
FWCI: 123.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: erlotinib, carboplatin, paclitaxel, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, combination chemotherapy, never smokers, overall survival, time to progression, objective response, maintenance therapy
MeSH terms: Erlotinib Hydrochloride, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Placebos, Quinazolines, Survival Analysis, Carboplatin, Paclitaxel, Disease Progression, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks